Key keywords: human cancer models, precision oncology, preclinical cancer research acceleration, patient-derived xenografts (PDX), cancer organoids, targeted therapy development, immunotherapy response prediction, rare cancer research For decades, traditional cancer research relied heavily on immortalized cancer cell lines cultured in lab dishes and generic mouse tumor models, which failed to capture the complex genetic heterogeneity, tumor microenvironment, and treatment response variability of actual patient tumors. This gap contributed to the staggering 90% failure rate of candidate cancer drugs in clinical trials, wasting billions in research funding and delaying life-saving treatments for millions of patients globally. Recent breakthroughs in human cancer model development are addressing this long-standing bottleneck at an unprecedented pace. Next-generation models including patient-derived xenografts (PDX), 3D cancer organoids, tumor-on-a-chip systems, and CRISPR-edited isogenic tumor models closely recapitulate the biological features of primary patient tumors, from genetic mutations to immune cell infiltration and extracellular matrix structure. The global Human Cancer Models Initiative (HCMI), launched in 2016 by a consortium of leading cancer research institutions, has already generated over 1,500 standardized, publicly accessible patient-derived models covering 40+ cancer types, including understudied rare malignancies that were previously excluded from large-scale research. These models are dramatically accelerating every stage of cancer research. In preclinical drug development, researchers can screen thousands of drug candidates across hundreds of patient-matched models in weeks, identifying which patient subgroups are most likely to respond to a new therapy early in the development process, reducing unnecessary clinical trial enrollment of patients who will not benefit. For clinical care, patient-specific organoid models can be generated from biopsy samples in as little as 7 to 10 days, allowing oncologists to test dozens of approved therapy combinations to identify the most effective regimen for each individual patient, a core goal of precision oncology. Multiple recent clinical studies have validated the utility of these models: a 2024 trial of 320 late-stage gastrointestinal cancer patients found that treatments matched to organoid screening results had a 76% response rate, compared to 21% for standard empiric treatments. For rare cancers, which account for 25% of all cancer diagnoses but have very few approved treatments, biobanks of subtype-specific human cancer models are enabling targeted drug development for conditions that were once considered research dead ends. Regulators are also adapting to this shift: the U.S. Food and Drug Administration released new guidance in 2023 allowing preclinical data from human cancer models to support investigational new drug applications, reducing the requirement for unnecessary animal testing and speeding up therapy approval timelines.